Biocon to obtain approval for diabetes drug, Liraglutide in UK

Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus

Indranil Sen, CFO, Biocon resigned

Sen spent a decade with Biocon and held various key roles,

Biocon appoints Vishal Nayyar as Head – SCM and Amit Kaptain as Head Commercials - API

Biocon included in S&P Global Sustainability Yearbook 2024

Sustainability is integral to Biocon's business purpose

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million

Biocon signs commercialization agreement with Juno Pharmaceuticals in Canada

Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market

Biocon names Peter Bains as Group CEO

Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect

Biocon acquires oral solid dosage manufacturing facility of Eywa Pharma for US$7.7 million

The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year

Biocon posts Q4 FY23 consolidated PAT at Rs. 313.2 Cr

The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023

Biocon approves NCD issue

The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.